Maze Therapeutics (NASDAQ:MAZE) CMO Sells $434,677.13 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 16,141 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $26.93, for a total value of $434,677.13. Following the sale, the chief marketing officer directly owned 16,141 shares in the company, valued at $434,677.13. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Friday, September 4th, Harold Bernstein sold 9,705 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.22, for a total value of $254,465.10.
• On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total value of $134,965.89.
• On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $135,155.82.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.36, for a total value of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.61, for a total value of $445,680.62.

Maze Therapeutics Stock Performance

Shares of NASDAQ:MAZE opened at $26.43 on Monday. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a 12-month low of $21.95 and a 12-month high of $53.65. The business has a 50 day moving average of $26.97 and a two-hundred day moving average of $28.06. The company has a market capitalization of $1.47 billion, a PE ratio of -10.49 and a beta of 2.16.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). As a group, analysts forecast that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Tuesday, September 22nd. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Wedbush reissued an “outperform” rating and issued a $48.00 price objective on shares of Maze Therapeutics in a report on Wednesday, September 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday, September 21st. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $63.40.

Institutional Trading of Maze Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. boosted its holdings in Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after buying an additional 465,641 shares during the last quarter. TRV GP IV LLC acquired a new position in shares of Maze Therapeutics during the second quarter valued at approximately $133,502,907. ARCH Venture Management LLC acquired a new position in shares of Maze Therapeutics during the second quarter valued at approximately $122,983,582. BlackRock Inc. purchased a new position in shares of Maze Therapeutics in the second quarter valued at approximately $104,525,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Maze Therapeutics in the second quarter worth approximately $101,764,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.